| Not Yet Recruiting | A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotocl NCT07508995 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Precision Physical Exercise for Personalized Onco-Hematology. NCT07286539 | University of Salamanca | N/A |
| Recruiting | Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib NCT07428707 | National Heart, Lung, and Blood Institute (NHLBI) | EARLY_Phase 1 |
| Not Yet Recruiting | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite NCT07024706 | AstraZeneca | Phase 2 |
| Recruiting | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B NCT07221500 | Nurix Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients NCT07162532 | Assiut University | — |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refract NCT07205315 | Grit Biotechnology | EARLY_Phase 1 |
| Not Yet Recruiting | Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia NCT07113132 | Safaa Ali | — |
| Recruiting | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma NCT07030400 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Recruiting | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301 | Umoja Biopharma | Phase 1 |
| Recruiting | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated W NCT06788639 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | — |
| Recruiting | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011 | iOMEDICO AG | — |
| Completed | A Case Crossover Study of Intermittent Fasting in CLL/SLL NCT05708326 | British Columbia Cancer Agency | N/A |
| Recruiting | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409 | IDP Discovery Pharma S.L. | Phase 1 / Phase 2 |
| Recruiting | Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax NCT05724121 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom NCT05557695 | AstraZeneca | — |
| Recruiting | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Tr NCT04758975 | Paolo Ghia | Phase 2 |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma NCT05144347 | Exelixis | Phase 1 |
| Recruiting | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutu NCT04895436 | AbbVie | Phase 2 |
| Recruiting | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) NCT05168930 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intraveno NCT05105841 | AbbVie | Phase 2 |
| Recruiting | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137 | Nurix Therapeutics, Inc. | Phase 1 |
| Unknown | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies NCT04767308 | Huazhong University of Science and Technology | EARLY_Phase 1 |
| Withdrawn | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL NCT04685915 | Inhye Ahn | Phase 2 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Terminated | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement NCT04655261 | AbbVie | — |
| Active Not Recruiting | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) NCT04447768 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Terminated | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT04209621 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludara NCT04285567 | Hoffmann-La Roche | Phase 3 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or S NCT04419519 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic NCT04198415 | AbbVie | — |
| Completed | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic NCT03788291 | University of Rochester | Phase 2 |
| Completed | A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymph NCT03873857 | AbbVie | — |
| Recruiting | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Sma NCT03824483 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Suspended | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) NCT03659669 | AbbVie | — |
| Completed | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors NCT03771157 | University of Rochester | EARLY_Phase 1 |
| Completed | Dietary Intervention With High Phenolic EVOO in CLL NCT04215367 | University of Peloponnese | N/A |
| Completed | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Tr NCT03702231 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Unknown | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignan NCT03588598 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 |
| Completed | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Dele NCT03406156 | AbbVie | Phase 3 |
| Active Not Recruiting | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL NCT03580928 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Terminated | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib NCT03400176 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting NCT03342144 | AbbVie | — |
| Recruiting | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocyt NCT02966756 | AbbVie | Phase 2 |
| Active Not Recruiting | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies NCT03085173 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | Evaluation of the Immune Restoration Potential Of Lenalidomide NCT02371577 | University of California, San Diego | Phase 2 |
| Completed | A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has NCT02980731 | AbbVie | Phase 3 |
| Completed | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide NCT02793544 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938 | MEI Pharma, Inc. | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or AT NCT02580552 | miRagen Therapeutics, Inc. | Phase 1 |
| Terminated | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia NCT02538614 | Gilead Sciences | Phase 1 |
| Completed | Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patient NCT02553304 | National Health Research Institutes, Taiwan | — |
| Completed | informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia NCT02582879 | Pharmacyclics LLC. | — |
| Completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies NCT02265731 | AbbVie | Phase 1 / Phase 2 |
| Completed | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation NCT02226861 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re NCT02200380 | Celldex Therapeutics | Phase 2 |
| Terminated | A Phase II Study of Doxycycline in Relapsed NHL NCT02086591 | University of Rochester | Phase 2 |
| Completed | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Withdrawn | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (R NCT01754870 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT01976520 | XEME Biopharma Inc. | Phase 1 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Terminated | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chr NCT01463852 | Dartmouth-Hitchcock Medical Center | EARLY_Phase 1 |
| Completed | A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemi NCT01580228 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568 | Polyphor Ltd. | Phase 1 / Phase 2 |
| Completed | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) NCT01520922 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide NCT01723839 | Hackensack Meridian Health | Phase 2 |
| Completed | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic NCT01466153 | MedImmune LLC | Phase 2 |
| Completed | An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Re NCT01532700 | University Health Network, Toronto | Phase 2 |
| Completed | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit NCT01527838 | Fate Therapeutics | Phase 1 |
| Completed | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) NCT01419691 | University of Kansas Medical Center | Phase 2 |
| Terminated | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL NCT01203930 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukem NCT01188681 | Aptevo Therapeutics | Phase 1 / Phase 2 |
| Terminated | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL NCT01241786 | Hackensack Meridian Health | Phase 2 |
| Terminated | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a NCT01125787 | Nevada Cancer Institute | Phase 2 |
| Recruiting | Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins f NCT01087333 | National Cancer Institute (NCI) | — |
| Terminated | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764 | Everett Meyer | Phase 1 / Phase 2 |
| Completed | The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Con NCT00919321 | Tampere University Hospital | Phase 4 |
| Completed | Tumor Registry of Lymphatic Neoplasia NCT00889798 | iOMEDICO AG | — |
| Active Not Recruiting | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT NCT00840853 | Baylor College of Medicine | Phase 1 |
| Completed | Unrelated Umbilical Cord Blood (UBC)Transplantation NCT01768845 | West Virginia University | N/A |
| Completed | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic NCT00694590 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies NCT00710528 | Gilead Sciences | Phase 1 |
| Completed | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) NCT00640523 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lympho NCT00614042 | Aptevo Therapeutics | Phase 1 |
| Terminated | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia NCT00664677 | Erimos Pharmaceuticals | Phase 1 |
| Completed | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT00439231 | Georg Aue, M.D. | Phase 2 |
| Completed | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cell NCT00458679 | Baylor College of Medicine | Phase 1 |
| Completed | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia NCT00230282 | Steven E. Coutre | Phase 2 |
| Available | Expanded Access to Venetoclax NCT03123029 | AbbVie | — |
| Withdrawn | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendam NCT01131247 | Nevada Cancer Institute | Phase 2 |
| Approved For Marketing | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia NCT02136511 | Gilead Sciences | — |